Biosimilars Forum applauds legislators for leadership on proposed Medicare rule on biosimilars coding

The Biosimilars Forum is standing behind legislators in the U.S. House of Representatives who appealed to CMS to reconsider a proposed new rule that would lump biosimilars together for Medicare reimbursement purposes instead of assigning each product a unique code under the Healthcare Common Procedure Coding System.

The Biosimilars Forum is standing behind legislators in the U.S. House of Representatives who appealed to CMS to reconsider a proposed new rule that would lump biosimilars together for Medicare reimbursement purposes instead of assigning each product a unique code under the Healthcare Common Procedure Coding System. In a letter to the acting administrator, Andrew Slavitt, Reps. Joe Barton (R-TX) and Anna Eshoo (D-CA) and 33 of their colleagues warned that the change could pinch the number of biosimilars introduced in the United States and limit treatment options for patients here. "If this proposed rule is adopted as currently written, we fear that thousands of patients facing serious diseases and disorders who are expected to benefit from biosimilars may have limited access to these therapies," explained Michael Werner, Biosimilars Forum policy advisor.